7. Subsequent Events
|12 Months Ended|
Dec. 31, 2020
|Subsequent Events [Abstract]|
Note 7 – Subsequent Events
Subsequent to December 31, 2020, the Company received $332,750 in cash proceeds from the exercise of 151,250 warrants previously issued at an exercise price of $2.20. In addition, the Company received notices to exercise 1,580,140 warrants on a cashless basis resulting in issuance of 1,293,467 shares of common stock.
Subsequent to December 31, 2020, the Company entered into a transaction with HPI, a related party, to supply starting materials for the manufacturing of Berubicin API valued at $385,000.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef